Analyst Confidence Soars as Addus HomeCare Receives Multiple Price Target Upgrades

Market analysts are expressing strong bullish sentiment toward Addus HomeCare, with ten separate firms now recommending the stock as a buy opportunity. The consensus view suggests substantial upside potential, with average price targets indicating more than 20 percent growth from current trading levels.

Revised Price Targets From Leading Institutions

Several major financial institutions have recently updated their assessments of Addus HomeCare’s stock value:

• Stephens maintained its Overweight rating with a $140 target (September 3)
• RBC Capital Markets raised its target from $133 to $134 while keeping an Outperform rating (August 22)
• TD Cowen increased its target from $135 to $139, reiterating a Strong Buy recommendation (August 6)
• Barclays significantly adjusted its target upward from $83 to $109, despite maintaining an Underweight rating (August 19)
• JMP Securities reaffirmed its $150 target and Market Outperform stance (July 16)

The collective average price target now stands at $138.89, representing a notable 21.4 percent premium over the recent price of $114.36.

Strategic Expansion and Regulatory Support Drive Optimism

This wave of analyst upgrades follows strong fundamental performance. The company reported impressive second-quarter results, with revenue climbing 22 percent to reach $349.4 million. Adjusted earnings per share of $1.49 exceeded expectations by four cents.

Addus has pursued strategic growth through two significant acquisitions:
* The $21.3 million purchase of Helping Hands Home Care (completed August 2025)
* The $350 million acquisition of Gentiva’s personal care division (completed December 2024)

Should investors sell immediately? Or is it worth buying Addus HomeCare?

These transactions significantly strengthen Addus’s position in the Texas market and are projected to contribute approximately $280 million in additional annual revenue.

The company is also benefiting from favorable regulatory developments. Texas implemented a 9.9 percent budget increase effective September 1, providing Addus with an additional $17.7 million in funding. Illinois will follow with a 3.9 percent increase starting January 2026.

Leadership Transition and Future Outlook

Heather Dixon, formerly CFO of Acadia, is scheduled to assume the roles of President and Chief Operating Officer in mid-September. Her extensive healthcare industry experience is viewed as particularly valuable for the company’s next growth phase.

Market expectations remain elevated, with analysts projecting 2025 earnings of $4.59 per share. The upcoming third-quarter results in November will provide crucial insight into whether Addus can successfully translate its acquisition strategy and regulatory advantages into continued stock performance.